An elevated low density lipoprotein cholesterol is a major cause of atherosclerosis. Reducing the concentration of this lipoprotein stabilises atherosclerotic plaques, and may lead to regression of the atherosclerosis. A moderate reduction of the plasma concentration of this lipoprotein significantly decreases recurrent coronary events. Therapy is a combination of lifestyle modification, nutraceuticals and drug treatment. The most convenient and effective drugs are the HmGCoA reductase inhibitors or 'statins'. They control hyperlipidaemia and help to prevent myocardial infarction, unstable angina, sudden death and stroke.
Introduction
Hypercholesterolaemia is a major risk factor along with smoking, hypertension and diabetes for developing atherosclerosis. Coronary heart disease is almost entirely due to atherosclerosis in the coronary arteries. Atherosclerosis in the carotid arteries also plays a major role in stroke. Rupture of an atheromatous plaque in the coronary arteries is the pathological event underlying the acute coronary syndromes of sudden death, acute myocardial infarction and unstable angina.
Plaques that rupture are generally rich in cholesterol and the risk of coronary events is proportional to the serum cholesterol concentration, specifically low density lipoprotein cholesterol.
lipoproteins
The serum lipids are cholesterol and triglycerides. They are transported in the blood as large molecules known as lipoproteins. In addition to protein (apoproteins), cholesterol, cholesteryl esters and triglycerides, the lipoproteins also carry antioxidants such as vitamin E, dietary polyphenols and co-enzyme Q10. There are five major classes of lipoprotein (Table 1) . Intermediate density lipoprotein and low density lipoprotein (LDL) are the most atherogenic, while high density lipoprotein (HDL) is anti-atherogenic.
When triglycerides are elevated, this is usually associated with an elevation of very low density lipoprotein cholesterol (VLDL cholesterol). This lipoprotein has a triglyceride:cholesterol ratio of 2:1. When fasting triglyceride levels are greater than 1.5 mmol/L, the risk of coronary heart disease and stroke increases significantly. Fasting triglyceride levels greater than 1.9 mmol/L, compared to less than 1.5 mmol/L, increase the risk of coronary heart disease and stroke by more than 30%.
When there is an elevated serum cholesterol it is almost always due to an elevation of the LDL cholesterol. Occasionally an elevated cholesterol is due to a high concentration of HDL cholesterol, but these patients are not at increased risk of cardiovascular disease. As LDL cholesterol accounts for 60-70% of the total cholesterol and is atherogenic, it is the target of treatment in patients with hypercholesterolaemia.
Target concentrations
Patients must be assessed for other risk factors, the presence of cardiovascular disease and other causes of raised cholesterol to determine their absolute risk of a coronary event. 1 An appropriate target can then be set for their LDL cholesterol concentration.
A meta-analysis of randomised trials of statins showed that for each 1 mmol/L reduction of LDL cholesterol (which generally equates to a 20% reduction of LDL cholesterol) there is a 20-30% relative risk reduction of coronary heart disease events. 2 Lowering the LDL a further 30% or so, or an extra 1 mmol/L, reduces coronary heart disease events by a further 20-30%.
The target for an asymptomatic individual who has a low risk of developing coronary heart disease is an LDL cholesterol of Heart Foundation 3 and the American Heart Association guidelines. 4 Reducing LDL cholesterol to below appropriate targets is more important than the method or specific drug used to achieve the reduction. Traditional cuisines which are associated with low LDL cholesterol and low rates of heart disease are Mediterraneantype diets, as found in Greece, Italy and Spain, and cuisine low in total fat such as in Japan. It is also clear that a high intake of fish, particularly fish rich in marine omega-3 fatty acids, is associated with a low risk of heart attack and stroke.
After a myocardial infarction, a Mediterranean-type diet compared to a usual low fat diet is associated with a 50% relative reduction in mortality. This is independent of any change in serum cholesterol (see box). 6
Weight loss
Weight loss can favourably influence lipids irrespective of how it is achieved. For every kilogram decrease in body weight, LDL cholesterol decreases by 0.02 mmol/L, triglycerides decrease by 0.015 mmol/L and HDL cholesterol increases by 0.14 mmol/L. 7 Unfortunately, significant weight loss is difficult to achieve and maintain, but losing 5-10 kg is achievable and can make a difference to the risk profile.
exercise
Most exercise studies have indicated that regular aerobic exercise improves the lipid profile independent of diet and drugs. Regular exercise decreases LDL cholesterol by 10% and increases HDL cholesterol by 5%. 8 There is a dose response between the amount of exercise and lipoprotein changes.
Moderate aerobic exercise is defined usually as moderate effort of half an hour of intentional exercise most days of the week.
Nutraceuticals
The mediterranean diet after myocardial infarction 6 The healthy Mediterranean-type diet initially referred to the food traditionally eaten by the people of Naples. It was vegetarian-like, high in nuts and olive oil, vegetables and pasta which was cooked al dente. Fruit was eaten frequently along with some cheese, wine and nuts. The Mediterranean diet later extended to include the traditional diets of Crete and Spain.
The Lyon Diet Heart Study involved just over 600 individuals who had survived a myocardial infarction. After 3.5 years the trial was stopped early as there was a clear benefit for patients on the Mediterranean-type diet compared to a low fat diet.
The benefit was independent of drug therapy and serum cholesterol. 
Adverse effects of statins
If adverse effects occur, more than 90% appear within the first three months. Adverse effects tend to be dose related and are similar between statins. If a patient has adverse effects from one statin, the dose can be lowered, given in divided doses or every second day. Alternatively, the patient can be switched to another statin or a controlled-release formulation.
The common adverse effects are musculoskeletal aches.
Occasionally there is an associated increase in creatine kinase and rarely (less than 1/1000) a true myositis can occur. There is increased risk of myositis in those with renal failure, diabetes and in the elderly. If the creatine kinase is greater than 300 IU/mL, consider stopping the statin and repeat the test one week later. Long-term follow-up of patients in trials has not shown an increase in the risk of cancer from long-term exposure to statins.
Other drugs
In approximately 75% of the patients who cannot tolerate even half the usual dose of statins, ezetimibe can be effective. Nicotinic acid at a dose of 3 g per day lowers LDL cholesterol by about 20%, but more than 75% of patients cannot tolerate even half this dose due to severe flushing. Gemfibrozil has no effect on lowering LDL cholesterol.
Treatment of hypertriglyceridaemia
First-line treatment for elevated triglycerides (VLDL cholesterol) consists of a diet rich in mono-and polyunsaturated fat and low glycaemic index carbohydrate food, caloric restriction (leading to weight reduction) and exercise. The next step is consideration of marine omega-3 fatty acids (fish oil) and fibrates.
Conclusion
Elevated LDL cholesterol is a major risk factor for coronary heart disease and is the major target of therapy to prevent coronary events. In patients with clinical coronary heart disease, lowering the LDL cholesterol to less than 2.5 mmol/L lowers the relative risk of developing coronary events by approximately 25%, and lowering it to below 2 mmol/L reduces the relative risk by 50%.
Therapy involves diet, regular exercise, nutraceuticals and drug treatment along with attention to other risk factors. Statins are the first choice of drug therapy.
